Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can adding surgery or radiation to a targeted pill stop lung cancer longer?

NCT ID NCT03410043

First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 173 adults with stage IIIB or IV non-small cell lung cancer that has a specific EGFR mutation will take part. The goal is to see if combining local treatments with the drug works better than the drug alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • UCSF Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • University of Colorado

    Denver, Colorado, 80217-3364, United States

Conditions

Explore the condition pages connected to this study.